Skip to content
Screener

EBIT at other companies

Eli Lilly logo
Eli LillyLLY
$9.25B+36.4%
Amgen logo
AmgenAMGN
$3.51B+32.3%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$164.13M-196%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
-$45.69M-6.6%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$94.2M-95.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$3.19B+719%
Enterprise value$3.15B+798%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Calculated from MBX Biosciences, Inc.’s reported figures.

The source filing: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026. Open the filing →

Filed
May 7, 2026, 9:03 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-210593

FAQ

What is MBX Biosciences, Inc.'s EBIT?
MBX Biosciences, Inc. (MBX) reported EBIT of -$27.27M in Q1 2026.
How has MBX Biosciences, Inc.'s EBIT changed year-over-year?
MBX Biosciences, Inc.'s EBIT decreased by 2.8% year-over-year, from -$26.53M to -$27.27M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.

Ask your AI about MBX Biosciences, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude